JAK2V617F was the first driver mutation to be described [21, [25] [26] [27] and represents an activating mutation with a G to T somatic mutation at nucleotide 1849, in exon 14, resulting in the substitution of valine to phenylalanine at codon 617. Subsequent studies confirmed the presence of JAK2V617F in almost all patients with PV [28, 29] and in 50-60% of those with ET [30] [31] [32] [33] or PMF [34, 35] . In 2006, a somatic MPLW515L exon 10 mutation (a G to T transition at nucleotide 1544 resulting in a tryptophan to leucine substitution at codon 515 of the transmembrane region) was described in JAK2V617F-negative PMF [24] . In 2007, other JAK2 mutations (exon 12 JAK2) were described in JAK2V617F-negative patients with PV [36] . The most recent (December 2013) driver mutation to be described in MPN was CALR [22, 23] . With rare exceptions [37, 38] , CALR and MPL mutations are absent in PV and their frequencies are 20-25% and 3-4%, respectively, in ET, and 20-25% and 6-7% in PMF [35] . In other words, 10-15% of patients with PMF or ET do not express any one of the three mutations and are referred to as being "triple-negative" [35] . Most recently, whole exome sequencing revealed the presence of somatic or germline MPL or JAK2 variants in 3 of 8 triple-negative patients with MPN and subsequent MPL/JAK2 entire codon sequencing among 62 ET and 49 PMF triple-negative cases revealed novel somatic or germline MPL variants in 5 of 62 cases and JAK2 variants in 5 of 57 cases [39] .
Phenotypic Correlates of Driver Mutations
JAK2 mutations are generally associated with older age, higher hemoglobin level, leukocytosis, lower platelet count and increased risk of thrombosis in ET [40] . Mutant CALR in ET is associated with younger age, male sex, higher platelet count, lower hemoglobin level and lower leukocyte count and, in PMF, with younger age, higher platelet count and lower frequencies of anemia, leukocytosis, and spliceosome mutations [41] . About 80% of CALR mutated patients harbor one of two mutation variants: type 1, a 52-bp deletion (p.L367fs*46) or type 2, a 5-bp TTGTC insertion (p.K385fs*47). In ET, type 2 CALR mutation is associated with significantly higher platelet count [42] and, in PMF, with higher risk category, circulating blast percentage, leukocyte count, and inferior survival [43] . CALR variants that are neither type 1 nor type 2 are operationally classified into "type 1-like" and "type 2-like" variants, based on their structural similarities to type 1 and type 2 CALR variants, respectively, which is in turn based on alpha-helix content of the mutant C-terminus [44] . Most noteworthy is the survival advantage shown by PMF patients with type 1 or type 1-like CALR variants, compared to all other genotypes [44] . Most recently, the order of mutation acquisition was suggested as an additional determinant of phenotype in MPN [45] .
Pathogenetic Contribution of Mutations in Myeloproliferative Neoplasms
JAK-STAT activation might be the central theme in MPN pathogenesis [46] . JAK2 and MPL mutations are believed to directly activate JAK-STAT whereas CALR mutations might do the same indirectly, although mouse models suggest a primary effect on platelet production [47] . CALR is a multi-functional Ca 21 binding protein chaperone mostly localized in the endoplasmic reticulum (ER). CALR mutations often are exon 9 frame-shift mutations with somatic insertions or deletions, resulting in one base pair reading frame shift and an altered C-terminal that is missing the KDEL (lysine, aspartic acid, glutamic acid and leucine) ER retention motif and is positively rather than negatively charged. How these changes result in JAK-STAT or other pathway activation is currently being investigated.
Mutations or DNA sequence variants other than JAK2, MPL or CALR occur in a substantial number of patients with all three MPN [48] . The pathogenetic role of these other mutations is incompletely understood and might include cooperation with the driver mutations in facilitating disease progression [49, 50] . Specific genes affected in this regard include those relevant to epigenetic (e.g., ASXL1, TET2, EZH2, IDH1, IDH2, DNMT3A), RNA splicing (e.g., SRSF2, U2AF1, SF3B1) or transcriptional (TP53, IKZF1, NF-E2, CUX1) regulation. Mutations other than JAK2, CALR or MPL, which have been shown to have prognostic relevance in PMF, include ASXL1, SRSF2, EZH2, IDH1/2, and U2AF1 [51, 52] . In addition, TP53, IDH2, SRSF2, and SH2B3 mutations have been reported to be over-represented in blastphase MPN, suggesting their relevance in disease progression [48, 50, 53] . Most noteworthy in this regard is TP53 loss, which is believed to make JAK2-mutated patients vulnerable to leukemic transformation [48, 50] .
Advances in Diagnostics
Driver mutations in MPN are now formally integrated into the WHO diagnostic criteria for polycythemia vera (98% JAK2 mutational frequency), essential thrombocythemia (60% JAK2, 22% CALR and 3% MPL mutational frequency) and primary myelofibrosis (58% JAK2, 25% CALR and 7% MPL) [54] . These clonal markers are now effectively used to distinguish MPN from secondary/reactive erythrocytosis or thrombocytosis. In its most recent (2016) revision [54] , the WHO document lists the presence of driver mutations as one of several major criteria in the diagnosis of PV, ET and PMF (Table I ) [54] . However, these mutations lack specificity and are unable to distinguish ET from masked PV or prefibrotic PMF [55] [56] [57] [58] [59] . Accordingly, bone marrow morphology is now considered as another major criterion for the 2016 WHO diagnosis of all three MPN (Table I ) [54] . The inclusion of bone marrow morphology as a major criterion has allowed lowering of the threshold hemoglobin level for the diagnosis of PV from 18.5 g dL 21 in men and 16.5 g dL 21 in women to a hemoglobin level of 16.5 g dL 21 in men and 16 g dL 21 for women (or a hematocrit level of 49% in men and 48% in women) [54] . The proposed changes for revision of WHO diagnostic criteria in PV, ET and PMF are listed in Table I whereas the International Working Group for MPN Research and Treatment (IWG-MRT) criteria are used for diagnoses of post-PV and post-ET myelofibrosis [60] .
Advances in Prognostication
Mature survival data in MPN was recently published by the Mayo Clinic-Italian collaborative group [35] . In the particular study, among 826 Mayo Clinic patients with ET, PV or PMF, the respective median survivals were 20 years for ET, 14 years for PV and 6 years for PMF [35] ; the corresponding values for patients younger than age 60 years were 33, 24, and 15 years. The study also showed that lifeexpectancy in ET was inferior to that of the sex-and age-matched US population.
In over 1500 patients with PV, the IWG-MRT identified the following four variables as independent risk factors for survival: advanced age (age 67 with five adverse points and age 57-66 with two adverse points), leukocytosis (15 3 10 (9)/L with one adverse point), venous thrombosis (with one adverse point) and abnormal karyotype (not included in the clinical prognostic model) [61] . The first three risk factors were then used in a three-tiered prognostic model: low risk patients (0 adverse points) displayed median survival of 26 years; intermediate risk patients (1 or 2 adverse points) displayed a median survival of 15 years; high risk patients (3 or more adverse points) displayed median survival of 8.3 years [61] . Risk factors for leukemic transformation in PV include advanced age, leukocytosis and abnormal karyotype [61] whereas JAK2V617F allele burden of >50% has been associated with fibrotic transformation [62] .
In ET, the IWG-MRT studied 867 patients with WHO-defined ET and developed the International Prognostic System for ET (IPSET), which included the following risk factors: advanced age (60 years with two adverse points), leukocytosis (11 3 10(9)/L with one adverse point) and thrombosis history (with one adverse point) [63] . These three risk factors were then used in a three-tiered prognostic model: low risk patients (0 adverse points) displayed median survival that was not reached; intermediate risk patients (1 or 2 adverse points) displayed a median survival of 24.5 years; high risk patients (3 or more adverse points) displayed median survival of 14.7 years. JAK2/CALR mutational status did not affect survival in ET [64] . Risk factors for leukemic transformation in ET include thrombosis and extreme thrombocytosis (platelets >1000 3 10(9)/L) and for fibrotic transformation advanced age and anemia; the presence of JAK2V617F was associated with a lower risk of fibrotic transformation [65] .
Modern era prognostic modeling in PMF started with the development of the International Prognostic Scoring System (IPSS) in 2009 [66] , which was subsequently upgraded to the dynamic IPSS (DIPSS) in 2010 [67] and DIPSS-plus in 2011 [68] . DIPSS-plus includes 8 risk factors for survival: age >65 years, hemoglobin <10 g dL 21 , leukocyte count >25 3 10 9 /L, circulating blasts 1%, presence of constitutional symptoms, unfavorable karyotype (i.e., complex karyotype or sole or two abnormalities that include 18, 27/7q-, i(17q), inv(3), 25/5q-, 12p-or 11q23 rearrangement) [69, 70] , red cell transfusion need [71, 72] and platelet count <100 3 10 9 /L [73] . Based on these eight risk factors, four DIPSS-plus risk categories were generated: low (no risk factors), intermediate 1 (one risk factor), intermediate 2 (two or three risk factors) and high (four or more risk factors) with respective median survivals of 15.4, 6.5, 2.9, and 1.3 years [68] .
More recently, a number of DIPSS-plus-independent risk factors in PMF were identified and they include driver mutations other than type 1 or type 1-like CALR variants [44] , monosomal karyotype [74] , nullizygosity for JAK2 46/1 haplotype [75] , low JAK2V617F allele burden [76, 77] , presence or number [78] of IDH1/2 [51] , EZH2 [51] , SRSF2 [51] , or ASXL1 mutations [51] , and increased serum IL-8 [79] , IL-2R [79] or serum free light chain levels [80] . In a recent international study of 570 patients with PMF [81] , the authors reported the longest 
Background Information on Treatment in Myeloproliferative Neoplasms
In 1967, Louis Wasserman (1912 Wasserman ( -1999 , an American hematologist, led the organization of the Polycythemia Vera study Group (PVSG), in order to systematically study the natural history of PV, ET, and PMF and the value of treatment modalities that were being employed at the time [82] . A similar effort was carried out in Europe by Tiziano Barbui (b. 1938) , an Italian physician scientist, through the Italian group for hematological diseases in adults (GIMEMA) [83] [84] [85] . Historically, treatment in MPN was documented more in PV and included skeletal radiation therapy (1917) [86] , acetylphenylhydrazine (1918) [87] , potassium arsenite (1933) [88] , P-32 (1940) [89] , lead acetate (1942) [90] , nitrogen mustard (1950) [91] , triethylene melamine (1952) [92] , pyrimethamine (1954) [93] , busulfan (1958) [94] , 6-mercaptopurine (1962) [95] , pipobroman (1962) [96] , uracil mustard (1964) [97] , chlorambucil (1965) [98] , and dapsone (1966) [99] . Hydroxyurea and melphalan were added to the list in 1970 [100, 101] .
Before the initiation of the PVSG clinical trials, the two most frequently used therapeutic modalities in PV were phlebotomy and intravenous P-32. Phlebotomy has been the cornerstone of treatment in PV for over a century [102] . However, early retrospective studies in PV had suggested a superior median survival with myelosuppressive therapy as opposed to either no treatment (median survival 18 months) or treatment with phlebotomy alone (median survival close to 4 years) [103] . The results from the early PVSG-led clinical trials in PV favored treatment with phlebotomy alone (median survival of 12.6 years) compared to both P-32 (median survival of 10.9 years) and chlorambucil (median survival of 9.1 years); the significant difference in survival was attributed to an increased incidence of acute myeloid leukemia (AML) in patients treated with chlorambucil or P-32 [104] . However, myelosuppression by P-32 or chlorambucil appeared to reduce the risk of thrombotic complications, which provided the rationale to study hydroxyurea, by the PVSG, as an alternative and possibly safer cytoreductive drug [105] . These were the seminal studies by the PVSG that provided the evidence to perform phlebotomies in all patients with PV and use, in addition, hydroxyurea in patients at high risk for thrombosis.
Advances in the Treatment of Myeloproliferative Neoplasms
Current drug therapy in PV, ET, or MF is neither curative nor capable of prolonging life or preventing disease progression [106] . Accordingly, treatment indications in PV and ET are primarily directed at prevention of thrombohemorrhagic complications and secondarily towards alleviation of symptoms and in PMF mostly at alleviation of symptoms with the possibility of cure limited to patients undergoing allogeneic stem cell transplant (ASCT) [107] .
Polycythemia vera and essential thrombocythemia
Median survival in PV before the era of phlebotomy was reportedly <2 years [103] and the current figure of 14 years [35] is clearly an improvement and mostly attributed to aggressive phlebotomy that keeps the hematocrit below 45%; this was confirmed in a controlled study [84] . Therefore, phlebotomy is indicated in all patients with PV. In addition, patients with PV or ET might require treatment with aspirin and/or cytoreductive drugs, for lowering their risk of thrombosis or bleeding or control of their symptoms. In this regard, it is most important to identify patients whose risk of thrombosis is high enough to justify short-and long-term side effects of drugs.
The IWG-MRT recently revised its IPSET-thrombosis model in order to make it clinically actionable [40, 108] . Figure 1 summarizes these changes and also includes risk-adapted treatment strategies. The most important risk factor for arterial and venous thrombosis in MPN is previous history of arterial or venous thrombosis, respectively [109] . Therefore, ET and PV patients with thrombosis history are now confirmed to be at "high risk" for recurrent thrombosis and managed accordingly with hydroxyurea plus systemic anticoagulation for venous thrombosis and hydroxyurea plus once-daily aspirin for arterial thrombosis (Fig. 1) . In addition, based on the respective presence or absence of additional risk factors for arterial thrombosis (e.g., presence of JAK2V617F, CV risk factors), high risk patients might require twice-daily aspirin, in the context of arterial thrombosis, and addition of once-daily aspirin to systemic anticoagulation, in the context of venous thrombosis (Fig. 1) .
Older (age >60 years) patients are no longer considered "high risk," unless they have a history of thrombosis or are JAK2-mutated (Fig. 1) . In other words, older JAK2-unmutated patients without thrombosis history are now considered as being "intermediate-risk" and managed with hydroxyurea and once-or twice-daily aspirin, depending on the absence or presence of CV risk factors (Fig. 1) . However, the risk of thrombosis in these intermediate-risk patients is low enough to occasionally consider, on an individual basis, skipping cytoreductive therapy (Fig. 1) .
The recognition of JAK2V617F as an important risk factor for arterial thrombosis has enabled subclassification of the lower risk patients with ET into "very low risk" and "low risk" categories [108] . "Very low risk" disease is defined by the absence of the three major risk factors for thrombosis: history of thrombosis, JAK2 mutation and age >60 years. Patients with very low risk ET can be managed with "observation alone" or once-daily aspirin (81 mg) in the absence or presence of CV risk factors, respectively (Fig. 1) . "Low risk" disease is now defined by the presence of JAK2 mutation in young patients (age 60 years) without history of thrombosis. Patients with low risk disease are managed by once-daily or twice-daily aspirin in the absence or presence of CV risk factors, respectively (Fig. 1) . The rational for using twice-daily aspirin in the presence of at least two risk factors for arterial thrombosis is based on recent studies that suggested that twicedaily aspirin may work better than once daily dose in certain cases, which is possibly linked to inadequate 24-h coverage from once-daily aspirin because of increased platelet turnover in MPN [110] . Accordingly, we sometimes consider such a therapeutic approach in patients who seem to be resistant to once daily dosing or considered to be at a higher risk of arterial thrombosis (Fig. 1) . Of note, platelet count more than 1000 3 10(9)/L was associated with a lower risk of arterial thrombosis but increased risk of bleeding because of associated acquired von Willebrand syndrome [111] . Therefore, twice-daily aspirin is best avoided in patients with extreme thrombocytosis.
The utilization of aspirin therapy in PV is supported by controlled evidence [83] , which has also been used as a rationale to treat ET patients with arterial risk factors [112] . In terms of cytoreductive therapy, there is controlled evidence of value for chlorambucil or radiophosphorus in PV [113] , and hydroxyurea in high risk ET [85] . However, the use of chlorambucil and radiophosphorus was complicated by shortened survival because of the increased leukemogenicity of these drugs [113] . Pipobroman, another myelosuppressive drug used in Europe, was also recently implicated as being leukemogenic in PV [61, 114] while the use of yet another drug, anagrelide, in high risk ET, was associated with increased risk of post-ET MF [115] . Therefore, while the anti-thrombotic value of cytoreductive therapy in high risk PV and ET is well recognized, the only drug with adequate evidence of efficacy and safety, in this regard, is hydroxyurea, which is currently the first-line drug of choice in high risk PV or ET patients.
In patients who do not tolerate or are resistant to hydroxyurea therapy, data from non-controlled studies support the use of interferon-a or busulfan as second-line drugs of choice. There is adequate long-term safety information on these drugs, which have both been shown to significantly reduce JAK2 or CALR mutant allele burden, although the effect of such biologic activity on risk of thrombosis or survival is unknown [116] [117] [118] [119] [120] . The JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-intolerant/resistant PV, based on its ability to alleviate constitutional symptoms and reduce spleen size [121] . However, the drug has not been shown to modify the natural history of PV and carries significant short-term and longterm side effects [122] that undermine its utility and it is currently not recommended for use in PV, in the absence of refractory symptomatic splenomegaly or intractable pruritus that fail to respond to hydroxyurea, busulfan or interferon alfa [112] .
Myelofibrosis
Despite some controversies, current drug therapy for PMF is not curative and is unlikely to prolong survival; JAK inhibitors have so far not shown disease-modifying activity, including reversal of bone marrow fibrosis or induction of complete or partial remissions [123] . ASCT is the only treatment modality that can either cure or prolong life and is therefore recommended in either DIPSS-plus high (i.e., presence of at least four of the 8 DIPSS-plus risk factors) [68] or molecularly high (absence of type 1/type 1-like CALR mutation and presence of ASXL1 or related high risk mutation) [81] risk disease (Fig. 2) [124] . If ASCT is not feasible in such patients, investigational drug therapy is highly recommended. MF patients with DIPSS-plus intermediate-2 risk disease but not molecularly high risk (i.e., not expressing ASXL1 or other high risk mutation) are operationally assigned "intermediate risk" category for purposes of risk-adapted therapy (Fig. 2) . Both ASCT and investigational drug therapy are reasonable treatment approaches for such patients.
Risk-benefit balance for ASCT might not be favorable, as first-line therapy, in DIPSS-plus low or intermediate risk patients who are not molecularly high risk. Such patients can further be classified into "very low risk" and "low risk" but their management is mostly similar (Fig. 2) [44] . There is no evidence to support the value of specific therapy in asymptomatic patients with DIPSS-plus low or intermediate 1 risk disease. However, such patients might require therapy for symptomatic anemia, splenomegaly, nonhepatosplenic EMH, bone pain, EMH-associated pulmonary hypertension or constitutional symptoms. In both "very low" and "low" risk disease, observation alone is recommended, in the absence of symptoms (Fig. 2) . First-line drugs of choice in such patients are hydroxyurea for symptomatic splenomegaly [125] , androgens preparations [126] , prednisone [126] , danazol [127] , thalidomide 6 prednisone [128] [129] [130] or lenalidomide 6 prednisone [131, 132] for symptomatic anemia, splenectomy (or splenic radiotherapy for nonsurgical candidates) for splenomegaly that is resistant to conventional drug therapy [133] , involved field radiotherapy for nonhepatosplenic EMH might and ruxolitinib for severe constitutional symptoms that are resistant to hydroxyurea therapy [133] .
Promising investigational drugs in myelofibrosis
Pomalidomide is a second generation immunomodulatory drug. In a phase 2 randomized study, 25% of patients with anemia responded to the drug used alone or in combination with prednisone [134] . In a 
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subsequent phase 2 study of single agent pomalidomide, anemia response was documented only in the presence of JAK2V617F (24% vs. 0%) [135, 136] . Platelet response was seen in 58% of patients but the drug had limited activity in reducing spleen size. However, the results of a phase 3 study comparing pomalidomide with placebo did not show significant difference in anemia response, which was 16% for each arm, whereas platelet response was significantly better with pomalidomide [137] .
JAK inhibitors that have undergone or are undergoing phase 3 clinical trials in MPN include ruxolitinib, fedratinib, momelotinib, and pacritinib. Ruxolitinib is a JAK1/JAK2 inhibitor. Two randomized studies comparing ruxolitinib with either placebo or best supportive care have now been published and both showed the efficacy of the drug in reducing spleen size and alleviating constitutional symptoms [138, 139] . In the ruxolitinib clinical trial that compared the drug with "best available therapy" [139] , the spleen response was 28.5% with ruxolitinib vs. 0% without it; ruxolitinib therapy was associated with thrombocytopenia (44.5% vs. 9.6%), anemia (40.4% vs. 12.3%) and diarrhea (24.0% vs. 11.0%). The long-term outcome of ruxolitinib therapy in MF was recently reported and disclosed a very high treatment discontinuation rate (92% after a median time of 9.2 months) and the occurrence of severe withdrawal symptoms during ruxolitinib treatment discontinuation ("ruxolitinib withdrawal syndrome") characterized by acute relapse of disease symptoms, accelerated splenomegaly, worsening of cytopenias and occasional hemodynamic decompensation, including a septic shock-like syndrome [140] . The 3-year follow-up information on the companysponsored phase 3 study disclosed a 55% drug discontinuation rate and a slight but significant improvement in survival [141] . Furthermore, several reports have now associated ruxolitinib with serious opportunistic infections [122] .
The results of the phase 2 and phase 3 studies using fedratinib (a selective JAK2 inhibitor) are now published [142, 143] . The phase-3 study (n 5 289) compared fedratinib at two different doses (400 or 500 mg day 21 ) with placebo and confirmed the efficacy of the drug in inducing spleen (36, 40 , and 1%, respectively) and symptom response (36, 34 , and 7%) [142] . Side effects of fedratinib included anemia, gastrointestinal symptoms, and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes. Encephalopathy was reported in four women who received fedratinib at 500 mg daily dose and was consistent with Wernicke encephalopathy in three cases; this resulted in the withdrawal of the drug from further development.
Momelotinib (JAK1 and JAK2 inhibitor) and pacritinib (JAK2 and FLT3 inhibitor) are currently undergoing phase 3 clinical trials [144] [145] [146] [147] [148] [149] . Among 100 consecutive Mayo Clinic patients treated with momelotinib, spleen or liver response rate was 43% and anemia response rate 44% [145] . Side effects of momelotinib included moderate to severe thrombocytopenia (35%), liver function test abnormalities (25%) and increased amylase or lipase levels (25%) and treatmentemergent peripheral neuropathy (44%). [144] . A recently published pacritinib study of 35 patients with high or intermediate risk MF [149] , spleen response rate by MRI was 31% and the majority of patients also experienced symptomatic relief. The most frequent side effects of pacritinib were diarrhea (69%) and nausea (49%). Compared to other JAK inhibitors, the drug appeared to be less myelosuppressive.
The Future
Current MPN clinical research is focused on the development of prognostic biomarkers and development of drugs that can modify disease natural history. Data are emerging regarding the prognostic value of targeted deep sequencing and preliminary data are scheduled to be presented at the December 2015 annual meeting of the American Society of Hematology. In terms of treatment, the limitation of JAK inhibitors to disease palliation is now well recognized and there is a dire need for disease-modifying drugs. In this regard, two papers on the telomerase inhibitor imetelstat were recently published in the New England Journal of Hematology and showed a potential diseasemodifying activity through the induction of clinical, histological and molecular remissions in both ET and PMF [150, 151] . In PMF [151] , imetelstat produced complete or partial remissions in 21% of 33 patients with high-or intermediate-2-risk disease. In addition, bone marrow fibrosis was reversed in all four patients who had a complete response, and a molecular response occurred in three of the four patients. Response appeared to be positively influenced by the presence of JAK2 mutation (27% vs. 0%) and absence of ASXL1 mutation (32% vs. 0%); similarly, the rate of complete response was 38% among patients with a mutation in SF3B1 or U2AF1 versus 4% among patients without such mutations. In ET [150] , 18 patients were treated with imetelstat and all 18 achieved hematologic response and 16 complete hematologic response. In addition, molecular responses were seen in 7 of 8 JAK2-mutated ET patients and reduction in mutant allele burden was also seen in CALR and MPL mutated patients. Severe myelosuppression and mostly reversible low grade abnormalities in liver function tests were the two main side effects of treatment with imetelstat [150, 151] .
The current paucity of disease-modifying drugs in MF reinforces the early consideration of ASCT in DIPSS-plus high or intermediate 2 risk or molecularly high risk disease [152] . The introduction of nextgeneration sequencing in routine clinical practice provides the opportunity to genetically refine current prognostic models in MF. In lower risk disease MF or in patients who are not good candidates for ASCT, my preferred treatment approach is observation alone, in asymptomatic patients, or participation in clinical trials, in patients requiring therapy.
